Anaptysbio Inc ANAB

$48.10 +0.16 (0.33%)

Valuation

Market cap
1,433,166,000
Revenue TTM
$234,600,000
Net income TTM
$-13,230,000
PE ratio
302.87
Forward PE
—
Profit margin
-5.64%
Debt to equity
0.00

Trading

Volume
254,900
Avg volume
514,092
Day's range
$46.83 – $48.51
Shares out
29,895,000
Stochastic %K
52%
Beta
0.76
Analysts
Strong Sell
Price target
$86.56

Price

Company profile

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular...

Show more

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 362 6295
Website
https://www.anaptysbio.com
Address
10770 Wateridge Circle, Suite 210, San Diego, United States

Latest news

Stocktwits

Merlintrader Oct 19, 8:54 PM
Latest company news, October 19, 2026: GSK says the FDA approved Jemperli under accelerated approval for MSI-H/dMMR locally advanced rectal cancer, ahead of the February 2027 target it had announced. For AnaptysBio any effect would run through the royalty on GSK's net sales, not through cash already received. AnaptysBio $ANAB Stock: Quimilza PDUFA, Jemperli Royalties and Risks Not investment advice. More details in our stock hub.
0 replies
notreload_ai Oct 19, 6:58 PM
FDA grants accelerated approval to $GSK Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending $ANAB stock higher on royalty potential. https://notreload.xyz/xy/anaptysbio-rises-on-jemperli-fda-approval-for-rectal-cancer/
0 replies
filecrux Oct 19, 6:32 PM
$ANAB (Anaptys, collects royalties on GSK's cancer drug Jemperli): the FDA approved Jemperli in stage II/III MSI-H/dMMR rectal cancer ahead of its Feb 2027 PDUFA date, with 68% of evaluable patients (98/144) in a sustained 12-month complete response by investigator assessment. By central review, the primary measure, it's 47% so far. Market value ~$1.47B at $49.27 (14:28 ET Oct 19, 2026); cash and investments $164.1M at June 30, 2026. But royalties first repay ~$299M non-recourse Sagard debt, paydown seen 2H 2027. Full data at ESMO Oct 25.
0 replies
Rayvio_News_Filter Oct 19, 6:20 PM
$GLAXF · $ANAB 🏥 GSK received FDA approval for Jemperli (dostarlimab) as the first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer, based on AZUR-1 data.
0 replies
Merlintrader Oct 17, 4:34 PM
📅 CATALYST REMINDER | $ANAB October 20 & 25, 2026 — Legal Hearing & Phase 2 Data October 20: post-trial hearing in GSK/Tesaro Jemperli litigation (not a judgment date). October 25: AZUR-1 Phase 2 dostarlimab data in locally advanced dMMR/MSI-H rectal cancer at ESMO. More details in our hub. #ANAB #Biotech #Litigation
0 replies
Merlintrader Oct 9, 11:31 AM
Latest company news, September 21, 2026: AnaptysBio reported cash and investments of 164.1 million dollars; the Sagard paydown is estimated in the second half of 2027. AnaptysBio $ANAB Stock: Quimilza PDUFA, Jemperli Royalties and Risks https://www.merlintrader.com/anaptysbio-stock-hub/
0 replies
Quantumup Sep 30, 12:03 PM
Canaccord Genuity🏁 $TRAX and said -- We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12-month price target of $50. $ANAB ENTO FBRX TAK SNY TEVA $EPRX AZN BMY PHAT ABBV GILD REGN PFE LLY Canaccord Genuity added—The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis (EoE) in 3Q27. The remaining 5% of our valuation comes from rosnilimab, which recently reported positive Phase IIb data in rheumatoid arthritis but is paused pending a partner for Phase III development.
0 replies
eWhispers Sep 22, 2:05 PM
#earnings moves for Tuesday, September 22, 2026 $AZO $ABVX $THO $ANAB $MLKN
0 replies